Vercellino L.,Hospital Saint Louis |
Groheux D.,Hospital Saint Louis |
Thoury A.,Hospital Saint Louis APHP |
Delord M.,Universitary Institute of Hematology Paris |
And 7 more authors.
Clinical Nuclear Medicine | Year: 2012
PURPOSE: Our aims were to assess the feasibility of imaging hypoxia in cervical carcinoma with F-fluoroerythronitroimidazole (F-FETNIM) and to compare F-FETNIM uptake with metabolic uptake of F-FDG. PATIENTS AND METHODS: We included 16 patients with cervical carcinoma. After imaging with FDG, F-FETNIM PET/CT was performed and tumor-to-muscle (T/M) ratio uptake was assessed. F-FETNIM uptake was correlated to FDG uptake and osteopontin (OPN), a marker of hypoxia, and patients' outcomes. RESULTS: All tumors were detected by F-FDG PET. F-FETNIM T/M ratios ranged from 1.3 to 5.4. There was no significant correlation between F-FETNIM and F-FDG uptake. High F-FETNIM uptake (T/M > 3.2) was associated with reduced progression-free survival (log-rank = 0.002) and overall survival (log-rank = 0.02). Osteopontin ranged from 39 to 662 μg/L (median, 102.5 μg/L). Patients with OPN greater than 144 μg/L had reduced progression-free survival compared with those with OPN less than 144 μg/L (log-rank = 0.03). We found no significant correlation between F-FETNIM uptake and OPN blood levels. CONCLUSIONS: Our preliminary results showed that a high uptake of F-FETNIM was associated with a worse progression-free and overall survival. Copyright © 2012 by Lippincott Williams & Wilkins.